Prospective randomized comparisons of ranitidine bismuth citrate (RBC) versus colloidal bismuth subcitrate (Denol)-based triple therapy for the treatment of H-pylori infection.

被引：0
|
作者：
Kung, NNS
Sung, JY
Yuen, WF
Li, TH
Ng, PW
Lai, WM
Leung, MF
机构：
[1] Chinese Univ Hong Kong, Hong Kong, Hong Kong
[2] United Christian Hosp, Dept Med, Hong Kong, Hong Kong
[3] United Christian Hosp, Dept Pathol, Hong Kong, Hong Kong
[4] United Christian Hosp, Dept Microbiol, Hong Kong, Hong Kong
来源：
GASTROENTEROLOGY | 1998年 / 114卷 / 04期
关键词：
D O I：
10.1016/S0016-5085(98)80774-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
G0780
引用
收藏
页码：A190 / A190
页数：1
相关论文
共 50 条
  • [1] A prospective randomized trial of one-week bismuth ranitidine citrate (RBC) triple therapies for H-pylori infection.
    Sung, JJY
    Chan, FKL
    Leung, WK
    Wu, JCY
    Suen, R
    Ling, TKW
    Lee, YT
    Cheng, AFB
    Chung, SCS
    [J]. GASTROENTEROLOGY, 1999, 116 (04) : A321 - A321
  • [2] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    [J]. GUT, 1997, 41 : A103 - A104
  • [3] Randomized comparison of ranitidine bismuth citrate (RBC)-based triple therapies for H-pylori (HP).
    Laine, L
    Estrada, R
    Trujillo, M
    Emami, S
    [J]. GASTROENTEROLOGY, 1997, 112 (04) : A192 - A192
  • [4] One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy:: A prospective randomized controlled trial
    Kung, NNS
    Sung, JJY
    Yuen, NWF
    Li, TH
    Ng, PW
    Lai, WM
    Lui, YH
    Lam, KN
    Choi, CH
    Leung, MF
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (03): : 721 - 724
  • [5] Metronidazole resistance does not influence the efficacy of triple therapy with ranitidine bismuth citrate (RBC), clarithromycin (CLA) and metronidazole (MET) for H-pylori (Hp) infection.
    van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    [J]. GASTROENTEROLOGY, 1998, 114 (04) : A323 - A323
  • [6] Three months therapy with ranitidine bismuth citrate (RBC) reduces H-pylori-associated gastritis and density of H-pylori but does not cure the infection.
    Graham, DY
    Walsh, JH
    Schubert, TT
    Lanza, FL
    Peura, DA
    Peterson, W
    Riff, DS
    Yardley, J
    Ciociola, AA
    Kong, S
    Wood, D
    Webb, DD
    [J]. GASTROENTEROLOGY, 1996, 110 (04) : A122 - A122
  • [7] Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection
    Mönkemüller, KE
    Hirschowitz, BI
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (05) : 661 - 665
  • [8] The influence of metronidazole (MET) resistance on the efficacy of two triple therapy regimens with ranitidine bismuth citrate (RBC) for H-pylori (Hp) infection
    Van der Wouden, EJ
    Thijs, JC
    van Zwet, AA
    Kooy, A
    Kleibeuker, JH
    [J]. GUT, 1998, 43 : A86 - A86
  • [9] High H-pylori eradication rate with a one week triple regimen containing ranitidine bismuth citrate (RBC)
    Gudjonsson, H
    Bardhan, KD
    Hoie, O
    Kristensen, ES
    Schuetz, E
    KliebeFrisch, C
    Duggan, AE
    [J]. GUT, 1997, 41 : A99 - A99
  • [10] Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with H-pylori infection
    Cestari, R
    Corti, G
    Formenti, A
    Galli, F
    Gatti, M
    Marotta, F
    Milesi, F
    Paterlini, A
    Piubello, W
    Ravelli, P
    Tonini, G
    Ubiali, P
    Valenghi, D
    Fina, P
    Olivieri, A
    Tosatto, R
    [J]. GUT, 1998, 43 : A83 - A84
12345